Immune resistance is a key challenge of cancer treatment, especially of immuno-oncology, in which tumors evade or suppress the immune response of the patient. The session "Immune Resistance" aims to grasp the mechanisms of immune evasion and how to overcome them in order to enhance therapeutic effectiveness.".
Cancer cells may evade immune attack by several mechanisms, such as antigen presentation downregulation, release of immunosuppressive molecules, recruitment of regulatory immune cells, and activation of immune checkpoint pathways. These mechanisms impede the efficacy of therapies like checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. Knowing these mechanisms is essential to develop therapies that restore or augment anti-tumor immunity.
The session covers strategies to overcome immune resistance, such as combination therapies, checkpoint blockade, adoptive cell therapies, and tumor microenvironment modulation. Biomarker-based approaches and genomic profiling aid in identifying patients at risk of immune resistance and determining personalized treatment. Current research emphasizes the targeting of immunosuppressive mechanisms, augmentation of T-cell function, and optimization of antigen recognition.
Participants will learn about the biology, clinical issues, and new solutions in immune resistance. This session highlights how overcoming immune evasion will improve immunotherapy outcomes, facilitate personalized cancer treatment, and advance precision oncology for improved patient care.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
